ATE448781T1 - Methoden zur hemmung der aktivität der osteoklasten - Google Patents

Methoden zur hemmung der aktivität der osteoklasten

Info

Publication number
ATE448781T1
ATE448781T1 AT00950797T AT00950797T ATE448781T1 AT E448781 T1 ATE448781 T1 AT E448781T1 AT 00950797 T AT00950797 T AT 00950797T AT 00950797 T AT00950797 T AT 00950797T AT E448781 T1 ATE448781 T1 AT E448781T1
Authority
AT
Austria
Prior art keywords
methods
trance
disclosed
osteoclasts
activity
Prior art date
Application number
AT00950797T
Other languages
English (en)
Inventor
Ramachandran Murali
Mark Greene
Masahiko Kinosaki
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE448781T1 publication Critical patent/ATE448781T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
AT00950797T 1999-07-28 2000-07-28 Methoden zur hemmung der aktivität der osteoklasten ATE448781T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14609499P 1999-07-28 1999-07-28
PCT/US2000/020502 WO2001008677A1 (en) 1999-07-28 2000-07-28 Methods of inhibiting osteoclast activity

Publications (1)

Publication Number Publication Date
ATE448781T1 true ATE448781T1 (de) 2009-12-15

Family

ID=22515834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950797T ATE448781T1 (de) 1999-07-28 2000-07-28 Methoden zur hemmung der aktivität der osteoklasten

Country Status (7)

Country Link
EP (1) EP1207873B1 (de)
JP (1) JP4790179B2 (de)
AT (1) ATE448781T1 (de)
AU (2) AU778190B2 (de)
CA (2) CA2380007A1 (de)
DE (1) DE60043346D1 (de)
WO (1) WO2001008677A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2380009A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
US6884598B2 (en) 2000-09-22 2005-04-26 Immunex Corporation Screening assays for agonists and antagonists of receptor activator of NF-κB
WO2003004510A1 (de) 2001-07-03 2003-01-16 Febit Ag Zweistufige schutzgruppen für die synthese von biopolymeren
MX2009013354A (es) 2007-06-04 2010-07-06 Univ Ben Gurion Compuestos de triarilo y composiciones que los contienen.
CA2689518A1 (en) 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. A novel bone mass increasing agent
EP2279195B1 (de) * 2008-05-13 2013-05-15 Ashok Ranganath Shelar Medizinische anwendungen von auf basis von steroidem tigogenin synthetisierten benzoesäurehydrazonen
JP5876495B2 (ja) 2011-09-09 2016-03-02 住友電気工業株式会社 給電システム及び接続コネクタ
US9688794B2 (en) 2012-10-15 2017-06-27 Iowa State University Research Foundation, Inc. Tackifier compounds and methods of using the same
US9828332B2 (en) 2013-03-15 2017-11-28 PharmatorophiX, Inc. Non-peptide BDNF neurotrophin mimetics
US9828330B2 (en) 2013-03-15 2017-11-28 Pharmatrophix, Inc. Non-peptide BDNF neurotrophin mimetics
US9321803B2 (en) * 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
WO2015068156A1 (en) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
US10077257B2 (en) 2015-04-06 2018-09-18 Iowa State University Research Foundation, Inc. Aziridinated triglycerides and polymers formed therefrom
US10392471B2 (en) 2015-05-14 2019-08-27 Iowa State University Research Foundation, Inc. Polymers and methods of making the same
CN108064231A (zh) 2015-05-20 2018-05-22 国立大学法人大阪大学 具有炎性细胞因子分泌抑制活性的寡肽
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
CN111686116B (zh) * 2020-06-08 2021-05-04 广东省微生物研究所（广东省微生物分析检测中心） 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274987C (en) * 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
EP2009025B1 (de) * 1998-05-14 2011-07-27 Immunex Corporation Verfahren zur Hemmung der Wirkung der Osteoklasten
AU762749B2 (en) * 1998-07-01 2003-07-03 Trustees Of The University Of Pennsylvania, The Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
PL196790B1 (pl) * 1998-09-15 2008-01-31 Pharmexa As Zastosowanie zwierzęcego polipeptydu OPGL lub jego podsekwencji, lub analogu OPGL, zastosowanie fragmentu kwasu nukleinowego, zastosowanie wektora przenoszącego fragment kwasu nukleinowego, zastosowanie niepatogennej transformowanej komórki, zastosowanie kompozycji zawierającej taki fragment lub wektor, sposób identyfikacji zmodyfikowanego polipeptydu OPGL, sposób wytwarzania kompozycji immunogennej
CA2380009A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis

Also Published As

Publication number Publication date
WO2001008677A1 (en) 2001-02-08
WO2001008677A8 (en) 2001-07-12
DE60043346D1 (de) 2009-12-31
AU6384600A (en) 2001-02-19
AU778190B2 (en) 2004-11-18
EP1207873B1 (de) 2009-11-18
JP4790179B2 (ja) 2011-10-12
AU2005200650B2 (en) 2007-11-15
CA2380007A1 (en) 2001-02-08
AU2005200650A1 (en) 2005-03-10
CA2647796A1 (en) 2001-02-08
EP1207873A4 (de) 2006-04-12
EP1207873A1 (de) 2002-05-29
JP2003505503A (ja) 2003-02-12

Similar Documents

Publication Publication Date Title
ATE448781T1 (de) Methoden zur hemmung der aktivität der osteoklasten
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
HK1072541A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
ATE464886T1 (de) Verbessertes transdermales therapeutisches system für die behandlung der parkinson-krankheit
DE60041147D1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
WO2004110302A3 (en) Methods of delivering anti-restenotic agents from a stent
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
GB9216859D0 (en) Medicaments
TW200608965A (en) Medicine for prevention or treatment of diabetes
DE69630523D1 (de) Verwendung von Calciumkanalanantagonisten zur Behandlung von Herz-, Nieren-, Magen-und Darmkrankheiten sowie Bluthochdruck
Gray et al. The role of innominate artery ligation in the management of massive haemorrhage from tracheo-innominate artery fistula
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties